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Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent causes of abnormal liver
function. Because fatty acids can damage biological membranes, fatty acid accumulation in the liver may be
partially responsible for the functional and morphological changes that are observed in nonalcoholic liver disease.
The aim of this study was to use gas chromatography-mass spectrometry to evaluate the fatty acid composition of
an experimental mouse model of NAFLD induced by high-fat feed and CCl4 and to assess the association between
liver fatty acid accumulation and NAFLD. C57BL/6J mice were given high-fat feed for six consecutive weeks to
develop experimental NAFLD. Meanwhile, these mice were given subcutaneous injections of a 40% CCl4-vegetable
oil mixture twice per week.
Results: A pathological examination found that NAFLD had developed in the C57BL/6J mice. High-fat feed and
CCl4 led to significant increases in C14:0, C16:0, C18:0 and C20:3 (P < 0.01), and decreases in C15:0, C18:1, C18:2
and C18:3 (P < 0.01) in the mouse liver. The treatment also led to an increase in SFA and decreases in other fatty
acids (UFA, PUFA and MUFA). An increase in the ratio of product/precursor n-6 (C20:4/C18:2) and n-3 ([C20:5
+C22:6]/C18:3) and a decrease in the ratio of n-6/n-3 (C20:4/[C20:5+C22:6]) were also observed.
Conclusion: These data are consistent with the hypothesis that fatty acids are deranged in mice with non-
alcoholic fatty liver injury induced by high-fat feed and CCl4, which may be involved in its pathogenesis and/or
progression via an unclear mechanism.
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Background
Nonalcoholic fatty liver disease (NAFLD) encompasses a
spectrum of conditions that are histologically character-
ized by hepatic steatosis in individuals without signifi-
cant alcohol consumption and with no viral, congenital,
or autoimmune liver disease markers [1]. It is associated
with insulin resistance and metabolic syndrome [2,3].
Despite the many possible etiologies of NAFLD [4,5],
these results reflect the accumulation of lipids within
the hepatocyte cytoplasm.
High-fat feed ingestion and hepatic toxins (such as
CCl4) may lead to fatty acid accumulation and hepatic
damage. Hepatic lipid accumulation in hepatocytes
(hepatic steatosis) is the hallmark of NAFLD and an
important factor that can induce insulin resistance, lipid
peroxidation, changes in energy metabolism, hepatic cell
damage and inflammation. Fatty acid are the simplest
lipids. They are the basic components of more complex
lipids (including triglycerides, phospholipids and sphin-
golipids) and an important metabolic fuel. The composi-
tions of the lipids that accumulate in livers of subjects
with NAFLD are not well characterized. Most of the
published literature has focused on triglycerides accu-
mulation as the key defect in NAFLD [6,7]. However, it
is unknown whether there are substantial changes in
other lipid classes, such as fatty acid. Although an
increase in the n-6/n-3 fatty acid ratio in the total lipids
has been observed in NAFLD [8,9], the composition of
fatty acid in the hepatic lipids has not been extensively
characterized.
T h ep a t h o g e n i cm e c h a n i s mi n v o l v e di nt h ed e v e l o p -
ment of fatty liver is unclear. In alcoholic patients with
asymptomatic fatty liver and in morbidly obese patients,
free fatty acid accumulation was observed in liver
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any medium, provided the original work is properly cited.extracts [10,11]. Non-alcoholic steatohepatitis patients
had significantly higher concentrations of total and free
fatty acid in their plasma, compared with healthy indivi-
duals [12]. Changes in the fatty lipid composition may
be implicated in the pathogenesis of NAFLD. As yet,
there is little information available concerning the hepa-
tic lipid fatty acid composition in NAFLD [13]. The aim
of this study was to compare the liver fatty acid profiles
and detailed compositions of healthy mice vs. mice with




All of the sections in the experimental group exhibited
diffuse hepatic steatosis (Figure 1) under a light micro-
scope, whereas no fatty liver was observed in the control
group The relative sizes of the hepatic cell nuclei were
uneven. Hepatic steatosis (mostly microvesicular and
macrovesicular mixed steatosis) was most obvious
around the portal area and was accompanied by liver
cell necrosis and inflammatory cell infiltration. The lob-
ular and portal areas exhibited considerably more
inflammatory cell infiltration in the experimental group
than in the control group The total histological scores
of the livers in the model-group mice reached grade 2
or 3. In contrast to the control mice, a histological ana-
lysis of the livers from the mice treated with a high-fat
feed and a hepatotoxin (CCl4) confirmed marked fat
accumulation and revealed extensive inflammatory cell
infiltration, indicating that diffuse hepatic steatosis with
moderate inflammation (NAFLD) had developed.
Serological profiles
Twenty mice in each group were studied (Table 1). The
mice with NAFLD had significantly higher TC, HDL,
LDL, ALP, AST and ALT levels than did the mice in
the control group (P < 0.01), whereas the ALB level was
higher in mice with NAFLD than it was in control mice,
but this difference did not reach statistical significance.
However, the TG, TP and glucose levels were signifi-
c a n t l yl o w e ri nt h em i c ew i t hN A F L Dt h a ni nt h ec o n -
trol mice (P < 0.05 or P < 0.01).
T h i ss t u d yh a v es h o w e dt h a th i g h - f a tf e e da n dC C l 4
have pronounced effects on hepatic steatosis, decrease
the plasma TG level, and induce hepatocyte necrosis and
inflammatory cell infiltration. Serological and pathologi-
cal examinations confirmed that non-alcoholic fatty liver
injury developed in C57BL/6J mice in our study. The
blood levels of transaminase (AST, ALT and ALP) were
significantly elevated in the model mice, indicating liver
dysfunction and confirming the widely held belief that
serum transaminase is a sensitive indicator of liver injury.
The concentrations of serum TG and TC are known to
vary, depending on pathological factors [14]. Our results
revealed significantly higher TC levels (P < 0.01) and
Figure 1 Histological analysis of liver sections from mice that were fed a high-fat feed and control mice. Fresh sections were stained
with H&E to demonstrate lipid accumulation. (A) Control mouse liver. (B) Experimental mouse liver with severe hepatosteatosis consisting of
mixed microvesicular and macrovesicular fat accumulation.
Table 1 Serum characteristics of mice with or without
NAFLD
Parameters Controls Mice with NAFLD
TG (mmol/L) 0.74 ± 0.12 0.61 ± 0.11**
TC (mmol/L) 2.97 ± 0.35 4.65 ± 0.81**
HDL (mmol/L) 2.16 ± 0.43 2.87 ± 0.56**
LDL (mmol/L) 0.41 ± 0.09 0.83 ± 0.17**
TP (g/L) 82.69 ± 9.31 71.18 ± 9.45**
ALB (g/L) 39.67 ± 4.08 42.06 ± 2.33
GLU (mmol/L) 1.34 ± 0.32 0.94 ± 0.37*
ALT (IU/L) 64.71 ± 8.56 198.62 ± 12.36**
AST (IU/L) 56.32 ± 9.83 143.27 ± 17.38**
ALP (IU/L) 114.06 ± 13.62 149.83 ± 19.75**
The data are expressed as the mean ± SD (n = 20 per treatment group). *P <
0.05, ** P < 0.01 vs. control. ALT, alanine aminotransferase; AST, aspartate
aminotransferase; ALP, alkaline phosphatase; TG, triglycerides; TP, total
protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC, total
cholesterol; ALB, albumin; NAFLD, nonalcoholic fatty liver disease.
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mice than in the plasma of control mice. Decreased cir-
culating TG in the model mice indicated impaired hepa-
tic export of TG due to the high-fat feed and CCl4.T h i s
result does not support the evidence reported by Das and
De Almeida [12,15].
Hepatic fatty acid composition
The hepatic fatty acid compositions of the mice with or
without NAFLD are given in Table 2. The concentra-
tions of C14:0, C16:0, C18:0 and C20:3 were significantly
increased in the experimental group (P < 0.01), com-
pared with the control group, whereas the concentra-
tions of C18:1, C18:2 and C18:3 were significantly
decreased (P < 0.01). The SFA concentration was higher
in experimental group than in the control group (P <
0.01); this difference was largely due to significant
increases in C14:0, C16:0 and C18:0. While the polyun-
saturated fatty acid (PUFA) and monounsaturated fatty
acid (MUFA) concentrations were lower in the mice in
the experimental group than in the mice in the control
group (P < 0.01), this difference were mainly due to the
significant decreases (P < 0.01) in the C18:2, C18:3 and
C20:4 PUFA and the C18:1 MUFA.
The ratio of product/precursor n-6 (C20:4/C18:2) and
n-3 ([C20:5 + C22:6]/C18:3) in the mice in the experi-
mental group was higher than in the control group (P <
0.01), whereas the ratio of n-6/n-3 (20:4/[C20:5 +
C22:6]) in the mice in the experimental group was
l o w e rt h a ni nt h ec o n t r o lg r o u p .I na d d i t i o n ,t h eS F A /
TFA ratio was increased, and the UFA/TFA, PUFA/
TFA, PUFA/SFA and MUFA/SFA ratios were decreased
(Table 2).
High-fat feed has become popular in recent years as a
way to induce model of hepatic steatosis and steatohe-
patitis [16]. The accompanim e n to fah i g h - f a tf e e da n d
CCL4-mediated accumulation of fatty acid by hepatocyte
necrosis and inflammatory cell infiltration was unusual
because most other models of fatty acid accumulation
have been induced by high-fat feed [17]. High-fat feed
and CCl4 would be expected to produce hepatic fatty
acid accumulation and liver injury because the ingestion
of a large amount of fat and hepatic toxins (such as
CCl4) may trigger fatty acid accumulation. Mice with
NAFLD are a useful model to examine potential patho-
genic factors for non-alcoholic liver damage.
Altered lipid homeostasis in the liver is the pathophy-
siological hallmark of NAFLD [18]. This study, which
was conducted in model mice with histological and ser-
ological NAFLD, aimed to investigate the amounts and
types of fatty acid that accumulate within the liver in
NAFLD and whether their compositions might provide
some novel and interesting insights into the pathophy-
siology of NAFLD. Our findings clearly show that mice
w i t hN A F L Di n d u c e db yah i g h - f a tf e e da n dah e p a t o -
toxin (CCl4) exhibit fatty acid accumulation in the liver.
Furthermore, relatively similar profiles of SFA, PUFA
and MUFA were found in the hepatic fatty acid frac-
tions of the model and control groups. However, hexa-
decanoic acid (C16:0) and stearic acid (C18:0) were the
predominant saturated fatty acid, whereas octadecenoic
acid (C18:1) and linoleic acid (C18:2) were the predomi-
nant monounsaturated and polyunsaturated fatty acid,
respectively. The amounts of octadecenoic acid (C18:1)
and linoleic acid (C18:2) in both fractions were signifi-
cantly lower in the NAFLD group than in the control
group, whereas the amounts of C16:0 and C18:0 in the
saturated fraction were significantly higher in the
NAFLD group than in the control group. The high
levels of C16:0 and C18:0 may due to the lard, which is
rich in SFA, and they are important factors that can
lead to an increase in SFA. In addition, CYP450 can
convert CCl4 into chloroform radicals (CCl3￿), which
can inhibit Δ-9 desaturase activity in the liver cell
Table 2 The fatty acid content and ratios in the mice
liver
Fatty acid Control group Experimental group
C14:0 (μg/mg) 0.47 ± 0.13 2.39 ± 0.66**
C15:0 (μg/mg) 0.34 ± 0.12 0.18 ± 0.04**
C16:0 (μg/mg) 23.41 ± 7.72 70.08 ± 17.95**
C17:0 (μg/mg) 0.35 ± 0.11 0.41 ± 0.10
C18:0 (μg/mg) 11.07 ± 4.07 17.33 ± 5.15**
C18:1 n-9 (μg/mg) 93.87 ± 19.62 56.69 ± 19.08**
C18:2 n-6 (μg/mg) 84.96 ± 27.43 42.12 ± 22.11**
C18:3 n-3 (μg/mg) 2.76 ± 1.43 1.07 ± 0.66**
C20:1 n-9 (μg/mg) 0.94 ± 0.34 0.97 ± 0.38
C20:3 n-6 (μg/mg) 1.19 ± 0.44 2.10 ± 0.78**
C20:4 n-6 (μg/mg) 14.89 ± 5.18 11.10 ± 4.37
C20:5 n-3 (μg/mg) 0.64 ± 0.21 1.06 ± 0.57
C22:6 n-3 (μg/mg) 7.36 ± 4.76 6.57 ± 3.95
TFA (μg/mg) 242.24 ± 14.44 212.79 ± 11.95**
SFA (μg/mg) 35.64 ± 6.15 91.11 ± 6.92**
UFA (μg/mg) 206.60 ± 14.62 121.68 ± 12.07**
MUFA (μg/mg) 94.81 ± 10.53 57.66 ± 11.46**
PUFA (μg/mg) 111.80 ± 10.51 64.02 ± 8.38**
SFA/TFA ratio (%) 14.73 ± 2.44 42.89 ± 3.26**
UFA/TFA ratio (%) 85.27 ± 2.44 57.11 ± 3.43**
PUFA/SFA ratio (%) 323.23 ± 66.64 70.03 ± 11.05**
MUFA/SFA ratio (%) 273.63 ± 59.59 63.91 ± 14.62**
n-6/n-6 ratio (%) 18.04 ± 5.04 28.15 ± 8.90**
n-3/n-3 ratio (%) 286.69 ± 67.02 740.80 ± 58.75**
n-6/n-3 ratio (%) 188.29 ± 15.51 143.33 ± 13.66**
All of the values are expressed as mean ± standard deviation (SD) (n = 20 per
treatment group). TFA, total fatty acid; SFA, saturated fatty acid; UFA,
unsaturated fatty acid; PUFA, polyunsaturated fatty acid; MUFA,
monounsaturated fatty acid; n-6/n-6 ratio, C20:4/C18:2; n-3/n-3 ratio, (C20:5+
C22:6)/C18:3; n-6/n-3 ratio, C20:4/(C20:5+C22:6). **P < 0.01 vs. the control
group.
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into C16:1 and C18:1, respectively [19]. That may also
play an active role in the accumulation of C16:0 and
C18:0 in the liver. Indeed, liver damage has been
ascribed to the direct or indirect toxic effects of SFA
accumulation in the liver [20,21]. Barreyro et al showed
that excessive SFA (C16:0 and C18:0) accumulation in
hepatocytes could induce Bim and FasL expression,
increase stress in the endoplasmic reticulum, and cause
hepatocyte injury [22]. Another observation in this study
is that increased SFA in liver extracts is accompanied by
decreased MUFAs and a decrease in the MUFA/SFA
ratio. Saturated fatty acid accumulation at the expense
of MUFA has previously been reported in MCD-fed
mice, [11] suggesting that MUFA depletion may contri-
bute to liver injury. NAFLD is associated with several
factors, such as high saturated fat and cholesterol, which
inhibit Δ-6 and Δ-5 desaturase activity [23,24]. We
observed fatty acid accumulation in the liver and
decreased TG in the plasma, which may be implicated
in the pathogenesis of NAFLD.
Thus far, there are no available data regarding the pat-
tern of hepatic fatty acid in NAFLD patients. De
Almeida et al. compared the plasma fatty acid of NASH
patients and control patients [12]. Their results showed
that NASH patients had a significantly higher concen-
tration of free fatty acid, higher total saturated and
monounsaturated levels in both lipid fractions, and
increased hexadecanoic acid (C16:0) and octadecenoic
acid (C18:1) levels, compared with control patients.
There was also a progressive increase in MUFA (mainly
hexadecanoic and octadecenoic acid) that was associated
with the severity of the hepatic lesion [11]. Despite an
increase in hexadecanoic acid levels in NAFLD mice,
the octadecenoic acid content of the liver was decreased
in our study. The roles of these factors are a subject for
future studies.
One of the potentially important observations is
related to the PUFA changes in the NAFLD model.
There was a decrease in the downstream n-6 (arachido-
nic acid, 20:4n-6) and n-3 (linolenic acid, 18:3 n-3, and
docosahexanoic acid, 22:6 n-3) fatty acid in the NAFLD
model, which led to a decrease in the total amount of
PUFA and the PUFA/TFA and PUFA/SFA ratios. These
data suggest that a reduction in these fatty acid may be
a compensatory response to hepatotoxicity. This is sup-
ported by the possibility that a hepatotoxin (CCl4)a n d
NASH also decrease arachidonic acid and docosahexae-
noic acid levels [13,25]. Because these fatty acid are pre-
cursors for eicosanoids and other bioactive molecules
[26], decreased levels of these fatty acid may indicate
increased levels of eicosanoids, which play a role in the
progression or amelioration of hepatotoxicity. Studies by
Capanni et al. have shown that n-3 PUFA significantly
decrease fat accumulation in NAFLD mice [27]. Inter-
estingly, linoleic acid has previously been shown to act
as an endogenous anti-inflammatory molecule [28],
which may indicate that the decreased level of linoleic
acid in our high-fat-induced NAFLD model is also asso-
ciated with hepatotoxicity. Our results reinforce the
widely held belief that PUFA may play negative regula-
tory roles in the pathogenesis of NAFLD [29].
Arachidonic acid (20:4 n-6) is released from mem-
brane PLs by phospholipase A2 and from phosphatidyli-
nositol bisphosphate (through DAG) by phospholipase
C. Cyclooxygenase then rapidly converts arachidonic
acid into a pro-inflammatory metabolite that accelerates
the progression of hepatotoxicity [28,30]. It is possible
that the increased utilization of arachidonic acid (20:4
n-6) may also contribute to the observed decrease in
arachidonic acid levels in NAFLD. If this is true, phos-
pholipase and cyclooxygenase modulation may provide
another mechanism to control the inflammatory path-
ways of NAFLD.
It must be pointed out that the biological implications
of the changes in lipid composition are likely complex
and difficult to predict simply on the basis of the fatty
acid data. The biological effects of lipids depend on
their locations (membrane, cytosolic or nuclear) and
amounts [31,32]. They may function as key transcrip-
tional regulators (such as PUFA binding to sterol regula-
tory element binding protein-1c) or as regulators of
enzyme activity (such as PUFA affecting lipid oxidation).
Therefore, these hypothesis needs to be confirmed in
more focused studies.
The potential limitations of this study are natural
NAFLD in the model mice and the small study popula-
tion size of the test mice. It is possible that the lipid com-
position of the liver in the model mice may be different
from that of NAFLD patients, and the changes observed
in NAFLD mice may be even greater than those observed
in NAFLD patients. Despite the small study population
size, several findings reached statistical significance.
Conclusions
In summary, this study provides several observations
about the alterations in the fatty acid composition in
mice with NAFLD induced by high-fat feed and CCl4.
These observations may be significant for understanding
the pathophysiology of this condition. This study
demonstrates altered fatty acid compositions in mice
with or without NAFLD, an increase in SFA levels and a
decrease in UFA (MUFA and PUFA), arachidonic acid,
key n-3 fatty acid and the (n-6)/(n-3) fatty acid ratio. All
of these observations could play roles in the pathogen-
esis of NAFLD. They also provide a rationale for the use
of n-3 fatty acid supplementation as a treatment for
NAFLD.
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Drugs and reagents
All of the analytical-grade chemical reagents used in this
study were purchased from Tianjin Qianchen Weiye
Technology Development Ltd. (Tianjin, China), unless
otherwise indicated. The saturated fatty acid (SFA) and
unsaturated fatty acid (UFA) standards were purchased
from Sigma Chemical Company (St. Louis, MO, USA).
All of test kits used in this study were purchased from
HuiFeng (S.H.) Medical Science & Technology Co., Ltd.
(Shanghai, China), unless otherwise indicated.
Mouse treatments
Male C57BL/6J mice (9 to 10 weeks old) were purchased
from the Animal Center of Heilongjiang Provincial Can-
cer Hospital (Harbin, China), with the following produc-
tion license number: SCXK (HEI) 2006-008. The mice
were individually housed in our laboratory facility in
polycarbonate cages at a controlled temperature (21 to
25°C) and humidity (40 to 70%), with a twelve hour light/
dark cycle and free access to sterilized water and a stan-
dard pellet diet. After a one-week adaptive period, forty
mice were randomly divided into a control group (n =
20), which was fed a standard diet, and a experimental
group (n = 20), which was fed a high-fat feed (68.5% nor-
mal diet, 15% lard, 1% cholesterol, 0.5% bile and 15%
dextrin) for six consecutive weeks and, simultaneously,
subcutaneously injected with a 40% CCl4-vegetable oil
solution (a 0.07 mL/10 g dose in the first week and a 0.04
mL/10 g dose twice per week for the remainder of the
study). High-fat feed ingestion for six consecutive weeks
has been shown to induce hepatic lipid accumulation in
our laboratory (data not shown), and this dose of CCl4
has been shown to induce the development of hepatic
steatosis [33,34]. Twenty-four hours after the final treat-
ment, the mice were fasted to promote lipid accumula-
tion. The mice were euthanized with CO2 gas. At the
time of death, blood was collected from the thoracic
aorta. The serum was separated from the cellular ele-
ments by centrifugation. The livers were removed, rinsed
in ice-cold saline, and divided for various assays, as out-
lined below. All of the experimental protocols were
approved by the Northeast Agricultural University Ani-
mal Care and Use Committee prior to the initiation of
the study.
Laboratory evaluation
Serum alanine aminotransferase (ALT), aspartate amino-
transferase (AST), alkaline phosphatase (ALP), triglycer-
ides (TG), glucose (GLU), total protein (TP), albumin
(ALB), high-density lipoprotein (HDL), low-density lipo-
protein (LDL) and total cholesterol (TC) were deter-
mined using a Beckman CX4 automatic biochemical
analyzer (Beckman Coulter, Inc., USA).
Staining of tissue sections for pathology
Fresh liver tissue pieces from both groups of mice were
fixed in 10% neutral formalin, embedded in paraffin,
sliced and stained with H&E. The slides were examined
by a pathologist to detect the presence of fat, necrosis,
fibrosis and inflammation. The pathologist scored them
from 0 to 4 using the standards proposed by Dixon for
assessing changes in fat and inflammation [35]. The
sum of the fat, necrosis, inflammation and fibrosis
scores was termed the total histological score. The pre-
sence of NAFLD in mice was diagnosed using standard
criteria [36].
Extraction and derivatization of hepatic fatty acid
Frozen liver tissue samples (100 mg) were homogenized
in 1 mL of anhydrous diethyl ether. The homogenates
were subsequently extracted three times with anhydrous
diethyl ether and vigorous vortexing for 1 min, as pre-
viously described [37]. After centrifugation, the organic
layers were collected and combined, and the solvent was
evaporated at room temperature under a nitrogen
stream. The dry residue was redissolved in 1 mL of 0.5
mol/L KOH-methanol in a sealed vial in a 60°C bath
under an nitrogen stream for 10 min. Next, 1.5 mL of
13% methanolic BF3 was added, and the mixture was
incubated at 60°C for 30 min. Fatty acid methyl esters
were extracted with 1 mL of hexane and 2 mL of satu-
rated sodium chloride and separated and dried under
nitrogen stream. The dry residue was redissolved in 25
μL of hexane and prepared for gas chromatography
mass spectrometry (GC-MS) by sealing the hexane
extracts under nitrogen.
Liver fatty acid analysis
The derivatives were analyzed by GC-MS (HP6890N-
5973 Agilent, Hewlett-Packard, USA) with an electron
energy of 70 eV and a source temperature of 230°C.
The target compound (fatty acid methyl ester) was
detected by full-scan monitoring-mode recording of the
fragment ions at an m/z of 30 to 550. Calibration curves
were constructed over a concentration range of 0.25 to
125 μg/mL for unsaturated compounds and 0.1 to 100
μg/mL for saturated compounds. Heptadecanoic acid
(C17:0) was used as an internal standard. The calcula-
tions were based on the assumption of identical detector
responses for both the unsaturated and saturated fatty
acid. Calibration curves were generated for each of the
individual fatty acid and used for liver fatty acid quanti-
fication. They were based on the peak-area ratios and
linear in their tested ranges.
Data analysis
A statistics package (SPSS, version 13.0) was used for
the statistical analyses. The subject characteristics were
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means of each of the fatty acid were compared using
unpaired Student’s t-tests. Statistical significance was
considered to be P < 0.05.
List of abbreviations used
ALB: albumin; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST:
aspartate aminotransferase; GC-MS: gas chromatography mass spectrometer;
GLU: glucose; HDL: high-density lipoprotein; LDL: lower-density lipoprotein;
MUFA: monounsaturated fatty acids; NAFLD: nonalcoholic fatty liver disease;
PUFA: polyunsaturated fatty acids; SFA: saturated fatty acids; TC: total
cholesterol; TFA: total fatty acids; TG: triglyeride; TP: total protein; UFA:
unsaturated fatty acids.
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